The recent US FDA and European Commission approvals of sotorasib (AMG 510)2 and adagrasib (MRTX849)3, small molecule covalent KRASG12C-selective inhibitors, marked a milestone in the development of targeted therapies for KRAS-mutant cancers. Here, KRAS is linked to cancer.